000142914 001__ 142914
000142914 005__ 20240229112534.0
000142914 0247_ $$2doi$$a10.1016/S2214-109X(18)30452-2
000142914 0247_ $$2pmid$$apmid:30630775
000142914 0247_ $$2ISSN$$a2214-109X
000142914 0247_ $$2ISSN$$a2572-116X
000142914 0247_ $$2altmetric$$aaltmetric:53625411
000142914 037__ $$aDKFZ-2019-00542
000142914 041__ $$aeng
000142914 082__ $$a610
000142914 1001_ $$aHarris, Rebecca C$$b0
000142914 245__ $$aAge-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
000142914 260__ $$aOxford$$bElsevier$$c2019
000142914 3367_ $$2DRIVER$$aarticle
000142914 3367_ $$2DataCite$$aOutput Types/Journal article
000142914 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551349845_12795
000142914 3367_ $$2BibTeX$$aARTICLE
000142914 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142914 3367_ $$00$$2EndNote$$aJournal Article
000142914 520__ $$aTuberculosis is the leading single-pathogen cause of death worldwide, and China has the third largest number of cases worldwide. New tools, such as new vaccines, are needed to meet WHO tuberculosis goals. Tuberculosis vaccine development strategies mostly target infants or adolescents, but given China's ageing epidemic, vaccinating older people might be important. We modelled the potential impact of new tuberculosis vaccines in China targeting adolescents (15-19 years) or older adults (60-64 years) with varying vaccine characteristics to inform strategic vaccine development.A Mycobacterium tuberculosis transmission model was calibrated to age-stratified demographic and epidemiological data from China. Varying scenarios of vaccine implementation (age targeting [adolescents or older adults] and coverage [30% or 70%]) and characteristics (efficacy [40%, 60%, or 80%], duration of protection [10 years or 20 years], and host infection status required for efficacy [pre-infection, post-infection in latency, post-infection in latency or recovered, or pre-infection and post-infection]) were assessed. Primary outcomes were tuberculosis incidence and mortality rate reduction in 2050 in each vaccine scenario compared with the baseline (no new vaccine) scenario and cumulative number needed to vaccinate (NNV) per case or death averted, 2025-50.By 2050, results suggest that 74·5% (uncertainty interval [UI] 70·2-78·6) of incident tuberculosis cases in China would occur in people aged 65 years or older, and 75·1% (66·8-80·7) of all cases would be due to reactivation, rather than new infection. All vaccine profiles delivered to older adults had higher population-level impact (reduction of incidence and mortality rates) and lower NNV per case and per death averted than if delivered to adolescents. For an intermediate vaccine scenario of 60% efficacy, 10-year protection, and 70% coverage, the reduction of tuberculosis incidence rates with older adult vaccination was 1·9 times (UI 1·5-2·6) to 157·5 times (119·3-225·6) greater than with adolescent vaccination, and the NNV was 0·011 times (0·008-0·014) to 0·796 times (0·632-0·970) lower. Furthermore, with older adult vaccination, post-infection vaccines provided substantially greater mortality and incidence rate reductions than pre-infection vaccines.Adolescent-targeted tuberculosis vaccines, the focus of many development plans, would have only a small impact in ageing, reactivation-driven epidemics such as those in China. Instead, an efficacious post-infection vaccine delivered to older adults will be crucial to maximise population-level impact in this setting and would provide an important contribution towards achieving WHO goals. Older adults should be included in tuberculosis vaccine clinical development and implementation planning.Aeras and UK MRC.
000142914 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142914 588__ $$aDataset connected to CrossRef, PubMed,
000142914 7001_ $$aSumner, Tom$$b1
000142914 7001_ $$aKnight, Gwenan M$$b2
000142914 7001_ $$aEvans, Tom$$b3
000142914 7001_ $$aCardenas, Vicky$$b4
000142914 7001_ $$0P:(DE-He78)b3928caa1d0865f09ffc5cf5e7683da6$$aChen, Chen$$b5$$udkfz
000142914 7001_ $$aWhite, Richard G$$b6
000142914 773__ $$0PERI:(DE-600)2723488-5$$a10.1016/S2214-109X(18)30452-2$$gVol. 7, no. 2, p. e209 - e218$$n2$$pe209 - e218$$tThe lancet <London> / Global health Global health [...]$$v7$$x2214-109X$$y2019
000142914 909CO $$ooai:inrepo02.dkfz.de:142914$$pVDB
000142914 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b3928caa1d0865f09ffc5cf5e7683da6$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142914 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142914 9141_ $$y2019
000142914 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET GLOB HEALTH : 2017
000142914 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142914 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142914 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000142914 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000142914 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000142914 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ
000142914 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142914 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142914 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142914 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000142914 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000142914 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142914 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bLANCET GLOB HEALTH : 2017
000142914 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142914 980__ $$ajournal
000142914 980__ $$aVDB
000142914 980__ $$aI:(DE-He78)C070-20160331
000142914 980__ $$aUNRESTRICTED